With innovative trial designs and cutting-edge technologies, the oncology clinical trial landscape is going through a huge transformation. New and advanced therapies continue to emerge, holding promise for many patients. In pharmaphorum's oncology deep dive issue, our VP of Oncology shares the top 5 trends to watch for in the oncology trial space. Read now: https://hubs.la/Q02FXzTy0 #Oncology #ClinicalTrials #ClinicalResearch #Cancer #CancerTrials
Advanced Clinical’s Post
More Relevant Posts
-
Unlock the power of real-world oncology insights! Dive into our Lung Cancer reports, enriched with data from community physicians and KOL insights. Explore and preview these reports now: https://lnkd.in/evNzzxdT: #LungCancer #Oncology #SolidTumors
To view or add a comment, sign in
-
🆕 Have you seen our new Oncology animation? If you're looking to advance your cancer therapeutic, put Veristat’s global expertise in oncology to work for you, with regulatory and clinical insights and full-service execution across the development lifecycle. Take a look at our short video to learn how we can support your Oncology needs 👇 https://bit.ly/48Mv8dU #oncology #cancertherapeutics #VeristatYouTube
Specialized Oncology CRO from Consultation to Beyond Submission
To view or add a comment, sign in
-
MYC IHC could be crucial in tailoring immunotherapy approaches in NSCLC - Aakash Desai, MD, MPH ESMO - European Society for Medical Oncology Yash Ashara, MD Ying-Chun Lo https://lnkd.in/e_hr7nRp #Cancer #Oncology #LungCancer #OncoDaily #Oncology #lcsm
To view or add a comment, sign in
-
-
🔬 Diagnostic functional assays in oncology, a major step towards personalized medicine! 🔬 Every cancer patient requires special attention, ideally involving individualized treatment. The majority of patients today need chemotherapy to fight cancer effectively, but no test or biomarker can predict the effectiveness of treatments or combinations of treatments. Functional tests are an important tool in the choice of chemotherapy. A recent review showed that functional tests had an efficiency of 80% to identify the most effective treatment combination (Bounaix Morand du Puch et al.,Theranostics. 2021 Sep 21;11(19): 9538-9556). https://lnkd.in/ddNPEth4 #oncology #diagnostic #functionalassay #cancer #Oncogramme
To view or add a comment, sign in
-
-
Fantastic discussion on biomarker testing and precison oncology - Rafeh Naqash Ignacio Garrido-Laguna, MD, PhD, MBA Sunnie Kim Pashtoon Kasi https://lnkd.in/dE4frPjY #Cancer #ColorectalCancer #OncoDaily #Oncology #PrecisonOncology
To view or add a comment, sign in
-
-
With #SABCS23 in full swing, hear from Stefan Faderl, VP, Therapeutic Area Head, Oncology Clinical Development, as he delves into the science behind treating #HER2 positive #breastcancer with targeted therapies: https://lnkd.in/e8eDYyyU We recognize that a one-size-fits-all approach does not work in the treatment of #cancer, which is why we are pioneering new pathways into novel mechanisms for tumor types like breast cancer.
To view or add a comment, sign in
-
Join us tomorrow, Sunday, June 2, during the ASCO Annual Meeting for a groundbreaking poster presentation between 9:00 a.m. to 12:00 p.m. Our recent study utilizing the ConcertAI Oncology Dataset has revealed promising results for patients with metastatic castration-resistant prostate cancer. Through a collaboration with Merck and AstraZeneca our real-world analysis has demonstrated that early treatment with Olaparib monotherapy could potentially enhance the duration of therapy and overall survival rates for these patients. This study underscores the importance of leveraging data to make informed treatment decisions that can ultimately improve patient outcomes. Read abstract: https://hubs.ly/Q02z9qws0 #ASCO24 #OncologyResearch #RealWorldData #OlaparibMonotherapy #PatientCare
To view or add a comment, sign in
-
-
The ProPhet test could help us to tailor immunotherapy beyond just PD-L1 expression - Edgardo S. Santos, MD, FACP, FASCO (Florida Society of Clinical Oncology) #Oncology #Cancer #Research #OncoDaily #Immunotherapy #PDL1 #ProPhet
Edgardo S. Santos: The ProPhet test could help us to tailor immunotherapy beyond just PD-L1 expression - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
Highly recommended this webinar relevant for any one involved in the treatment of patients with lung cancer. Learn everything about drug-drug interactions, the pros and cons of TDM, and management of toxicity, including discussion of ESMO - European Society for Medical Oncology guidelines. You are all welcome!!
How are novel therapies influencing the treatment of lung cancer? 🔍 Our lineup of expert speakers will dive into the topic at our upcoming webinar, featuring discussion on drug-to-drug interactions, therapeutic drug monitoring, and immunotherapy. Don’t miss your chance to join this informative session on April 22. Early-career discounts apply. Register today 👉 amededu.co/3IL9MBZ #LungCancerDDIs #Oncology #LungCancer
To view or add a comment, sign in
-
-
Shortly commencing OV Precision Trial has now been registered at clinicaltrials.gov. It will be a landmark trial, applying precision oncological decision making using Tumor Profiler Center #TPC technologies in newly diagnosed ovarian cancer patients. HRD testing will examine the most desperate non-HRD patients, from whom we already know ow that they won’t respond to standard chemotherapy. Alternative information from TPC technologies will generate information for tge treating oncologist and allow alternative treatment decisions. #SwissGO. Swiss-GO - Designing innovative out-of-the-box trials in Gynecological Oncology
To view or add a comment, sign in
-
Felix Perez, CEO Research Director
1moExciting advancements in oncology trials! Your VP's insights on the top trends will surely illuminate the future of cancer research. #Oncology #ClinicalTrials #ClinicalResearch #Cancer #CancerTrials